Suboxone Settlement Calculator 2026: What the Dental Claim Record Shows
Use the Suboxone settlement calculator to organize potential dental-injury claim factors involving Suboxone film, including prescription history, tooth decay or erosion, damaged teeth, extractions, root canals, crowns, implants, future treatment, expenses, lost income and supporting records.
- Current August 3 JPML case count: 1,827 pending / 1,908 historical actions.
- Official court page now includes the July 16 provider-deposition order for Core Discovery Pool cases.
- FDA’s dental safety warning concerns buprenorphine medicines dissolved in the mouth; MDL 3092 is specifically the Suboxone Film litigation.
- Dental baseline, product identification, timing, procedures and records can materially affect case review.
- No bellwether verdict or court-approved payout matrix currently establishes a reliable average settlement.
Get Your Free Suboxone Claim Estimate
Answer the guided questions about Suboxone film use, dental injuries, treatment, expenses and supporting records.
Suboxone MDL 3092 Status in August 2026
In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, is centralized in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese. The court describes common allegations that Suboxone film can cause dental erosion and decay and that defendants failed to provide adequate warnings. Those allegations remain disputed.
1,827 Pending Actions
The August 3, 2026 JPML report lists 1,827 pending actions and 1,908 historical actions for MDL 3092. JPML counts actions, not a universal claimant population.
Core Discovery Is Underway
The March 27 bellwether protocol scheduled depositions for the 50-case Core Discovery Pool from July 13, 2026 through January 15, 2027.
Provider Depositions
The federal court’s current MDL page lists Case Management Order No. 23, entered July 16, 2026, governing provider depositions in Core Discovery Pool cases.
What the FDA Actually Reported About Buprenorphine Dental Problems
In January 2022, FDA required a new dental-risk warning for buprenorphine-containing medicines that dissolve in the mouth. Reported problems included tooth decay, cavities, oral infections, tooth erosion and tooth loss, including reports in people with no prior dental problems.
305 Reports
FDA identified 305 reported dental adverse-event cases in its review.
131 Serious
FDA classified 131 of the reported cases as serious.
113 Multi-Tooth
In 113 reports, two or more teeth were described as affected.
71 Extractions
Tooth extraction/removal was the most commonly reported treatment in the FDA case series.
Other reported treatment included root canals, dental surgery, crowns and implants. FDA also emphasizes that the reports do not establish how likely a dental event is for an individual patient and that the benefits of buprenorphine treatment clearly outweigh the risks for opioid use disorder and pain management.
Suboxone Dental Claims: What the Record Actually Shows
No Suboxone settlement exists, so there is no settlement range to publish. What follows is the actual record: what the manufacturer has told its investors, when the first trial is scheduled, how many claims are pending, and what the FDA found.
No settlement exists
None announcedIndivior’s Form 10-Q for Q2 2026 records no provision for this litigation and states that, given its preliminary stage, no estimate of possible loss can be made. There has been no settlement and no verdict in MDL 3092. Any dollar figure attached to a Suboxone dental claim today is a projection with no source behind it.
Indivior Form 10-Q, Q2 2026.Why no figure can exist yet
March 2028 at the earliestThe court’s Second Amended Case Management Order 15 sets a “March 2028 First Trial Setting.” Expert reports are due June 2027 and Rule 702 and summary judgment argument is not scheduled until January 2028. Indivior separately tells investors bellwethers will not occur before the end of the first quarter of 2028.
MDL 3092 case management order, 27 March 2026.Two counts that are not the same
1,827 actionsThe JPML report of 1 September 2026 counts 1,827 civil actions before Judge J. Philip Calabrese in the Northern District of Ohio. Indivior counts roughly 26,307 plaintiffs across about 1,967 cases, because multi-plaintiff complaints bundle many claimants into one docketed case. Both are correct; they measure different things.
JPML pending-MDL report; Indivior Form 10-Q.What the 2022 label change rested on
305 reported casesThe FDA Drug Safety Communication of 12 January 2022 described 305 dental adverse-event cases, 131 of them serious, reported through 31 December 2018, including 71 tooth extractions. Mean age was 41.8 years and median time to event 24.25 months; 26 cases involved people with no prior dental history. The FDA added warnings while stating that the benefits of buprenorphine clearly outweigh the risks.
FDA Drug Safety Communication, 12 January 2022.Why No Suboxone Settlement Figure Exists Yet
Search results for Suboxone dental claims are full of dollar figures. None of them comes from a settlement, because no Suboxone settlement exists. Indivior’s own filing with the Securities and Exchange Commission for the quarter ending 30 June 2026 records no provision for this litigation and says that, given its status and preliminary stage, no estimate of possible loss can be made. When the defendant tells its investors it cannot value the case, no outside party can credibly publish a per-claim range.
The timetable explains why. MDL 3092 is proceeding before Judge J. Philip Calabrese in the Northern District of Ohio on a bellwether structure that narrows a 500-case record pool to 50 for core discovery, then 15, then four trial cases. Core discovery depositions run to January 2027, expert reports are due June 2027, and Rule 702 and summary judgment argument is not scheduled until January 2028. The court’s own order names a March 2028 first trial setting. Nothing before that date will produce a verdict, and settlements in pharmaceutical MDLs typically follow bellwether results rather than precede them.
The case counts are also routinely misreported, in a way worth understanding before reading any coverage of this litigation. The Judicial Panel on Multidistrict Litigation counts civil actions, and reported 1,827 pending as of 1 September 2026. Indivior counts plaintiffs, and reports roughly 26,307 across about 1,967 consolidated cases, plus around 4,854 further claimants on Schedule A filings and more than 950 tolled claims in Delaware, New Jersey and Virginia state courts. A single complaint can carry hundreds of plaintiffs, which is why the two figures differ by more than fourteen times. Neither is wrong; they measure different units.
What the litigation actually rests on is the FDA’s January 2022 safety communication, which followed reports of dental problems in people taking buprenorphine medicines dissolved in the mouth. The agency described 305 cases reported through the end of 2018, 131 of them serious, including 71 tooth extractions and 113 cases involving two or more teeth. Median time from starting the medicine to the dental event was just over two years, and 26 of the reported cases involved people with no prior history of dental problems. The FDA required warnings in the prescribing information and the patient Medication Guide, while stating that the benefits of these medicines for opioid use disorder clearly outweigh the risks — a point that matters for anyone weighing whether to continue treatment.
For readers trying to understand how a mass tort reaches the point of paying anyone, our settlement amounts guides cover litigations at later stages, including several where amounts have been disclosed and several where they have not. The honest position on Suboxone today is that it is early, the science and causation questions are unresolved, and the first meaningful signal will be the bellwether outcomes in 2028.
Who May Need a Suboxone Dental Lawsuit Review?
Eligibility cannot be determined by a calculator alone. A case review generally examines the exact product used, use dates, dental condition before exposure, onset of injury, treatment, warnings, state law and the quality of supporting records.
Facts That May Support Closer Review
- Suboxone sublingual film use that can be confirmed through pharmacy, prescriber, clinic or insurance records
- Dental decay, erosion, infection, fracture or tooth loss after use
- Root canals, crowns, extractions, implants, dentures or reconstructive procedures
- Baseline dental charts or X-rays that help show pre-use dental condition
- Consistent dental and prescription timeline
- Documented past costs, future treatment, lost earnings or functional impact
Issues Requiring Individual Review
- Tablet-only, generic or uncertain product use
- Significant pre-existing decay, gum disease or missing teeth
- Smoking, severe dry mouth, trauma, diet or other competing dental risk factors
- Large gaps in pharmacy or dental records
- Long delay between injury, suspected cause and legal review
- Uncertain statute of limitation or statute of repose
6 Factors That Can Affect Suboxone Claim Value
1. Product Identification
Records showing Suboxone film, dispensing dates, prescriber and duration can be central to identifying the relevant defendant and legal theory.
2. Baseline Dental Health
Older dental charts and imaging can help distinguish later deterioration from pre-existing decay, periodontal disease or missing teeth.
3. Number of Teeth & Procedures
Multi-tooth decay, infection, root canals, crowns, extractions, implants and extensive reconstruction can materially increase treatment burden.
4. Future Dental Care
Replacement of restorations, implant maintenance, dentures, bone grafting and future reconstruction can create long-term costs.
5. Economic & Daily Impact
Out-of-pocket bills, missed work, diet limitations, speech problems, pain, appearance changes and other supported losses can affect damages.
6. Causation & State Law
Expert opinions, warnings, alternative causes, applicable state law and filing deadlines can materially change whether a claim succeeds.
Records That Can Strengthen a Suboxone Dental Claim
- Pharmacy dispensing history
- Prescriber and treatment-clinic records
- Insurance explanation-of-benefits records
- Product packaging or photographs when available
- Baseline dental examinations
- Dental X-rays and other imaging
- Treatment notes and procedure codes
- Root canal, crown and filling records
- Extraction, denture and implant records
- Future treatment plans and cost estimates
- Dental bills and insurance statements
- Wage-loss, photographs and daily-impact documentation
How the Suboxone Settlement Calculator Works
Suboxone Lawsuit Filing Deadlines Vary by State
There is no single nationwide filing deadline for every Suboxone dental-injury claim. State statutes of limitation and repose can depend on where the claim is filed, injury and diagnosis dates, when the person knew or reasonably should have known of a possible product connection, defendant identity, prior filings and tolling rules.
Suboxone Lawsuit, Settlement and Calculator Resources
Suboxone Settlement Calculator FAQ
Has a Suboxone dental settlement been announced?
No court-approved global personal-injury settlement or dental payout matrix appears in the current official MDL 3092 materials reviewed for this August 11, 2026 update.
How many Suboxone MDL actions are pending?
The August 3, 2026 JPML report lists 1,827 pending actions and 1,908 historical actions in MDL 3092.
What is the current bellwether phase?
The current protocol places the 50-case Core Discovery Pool in a deposition period scheduled from July 13, 2026 through January 15, 2027, with selection of a 15-case Trial Pool scheduled for January 29, 2027.
Does MDL 3092 include every buprenorphine product?
No. The federal proceeding is specifically titled the Suboxone Film Products Liability Litigation. FDA’s dental communication is broader and covers buprenorphine-containing tablets and films dissolved in the mouth.
Should I stop taking Suboxone because of dental problems?
Do not stop it suddenly without speaking with the prescribing clinician. FDA says abrupt discontinuation can cause withdrawal and may increase the risk of relapse, overdose and death.
What records are most important?
Pharmacy and prescriber records, baseline and follow-up dental charts, X-rays, procedure records, bills, future-care estimates and evidence of economic or daily-life impact can all be important.
Request a Confidential Suboxone Dental Injury Review
Use the calculator to organize Suboxone film use, dental injuries, procedures, costs and records, or request a confidential review of the information you already have.
Where These Figures Come From
Every figure on this page comes from a primary record: Indivior’s filings with the Securities and Exchange Commission, case management orders issued by the MDL 3092 court in the Northern District of Ohio, the FDA’s Drug Safety Communication of 12 January 2022, and the Judicial Panel on Multidistrict Litigation’s pending-case report dated 1 September 2026.
We publish no settlement value, payout tier or per-case average for Suboxone dental claims, because none exists. Any figure of that kind currently circulating — including tiered ranges running into the hundreds of thousands of dollars — is a projection produced by a marketing page, not a record of anything that has been paid. When the first bellwether results arrive, this page will report what they actually were.
Suboxone Litigation and Dental Safety Sources
JPML — August 3, 2026 MDL Report
Official federal report listing 1,827 actions pending and 1,908 historical actions in Suboxone MDL 3092.
Open JPML report →Northern District of Ohio — MDL 3092
Official court page identifying Judge J. Philip Calabrese, the litigation description and current case-management orders, including the July 16 provider-deposition order.
Open MDL 3092 court page →Second Amended CMO No. 15
Official March 27, 2026 bellwether protocol governing the Core Discovery Pool, deposition schedule, Trial Pool selection and proposed later trial schedule.
Open bellwether protocol →FDA — Buprenorphine Dental Warning
FDA’s January 2022 safety communication describing reported decay, cavities, oral infections, erosion, tooth loss, treatment and oral-care guidance.
Open FDA safety communication →
